Janney Montgomery Scott began coverage on shares of ProQR Therapeutics NV (NASDAQ:PRQR) in a research note released on Wednesday. The brokerage issued a neutral rating and a $7.00 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently weighed in on the company. Zacks Investment Research raised ProQR Therapeutics NV from a sell rating to a hold rating in a report on Friday, September 23rd. JMP Securities reiterated a buy rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Leerink Swann reiterated a buy rating on shares of ProQR Therapeutics NV in a research note on Thursday, August 18th. Finally, Chardan Capital assumed coverage on ProQR Therapeutics NV in a research note on Monday, June 20th. They issued a neutral rating and a $4.50 target price for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $14.15.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.72 on Wednesday. ProQR Therapeutics NV has a 52-week low of $3.48 and a 52-week high of $16.23. The firm’s market cap is $156.89 million. The firm has a 50-day moving average price of $6.05 and a 200-day moving average price of $5.26.
ProQR Therapeutics NV (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. Analysts predict that ProQR Therapeutics NV will post ($2.09) EPS for the current fiscal year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Sabby Management LLC raised its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned approximately 0.64% of ProQR Therapeutics NV worth $732,000 as of its most recent SEC filing. 39.21% of the stock is owned by institutional investors.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.